

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **UPDATE ON RECENT DEVELOPMENT OF SUSPENSION**

This periodic announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”).

Reference is made to the announcements of the Company dated 6 October 2017 and 12 January 2018 in relation to, among other matters, the letter dated 6 October 2017 issued by the Securities and Futures Commission of Hong Kong (“**SFC**”) to the Company and the suspension of trading in the Shares (“**Suspension**”), the announcements of the Company dated 25 May 2018, 4 June 2018, 1 August 2018, 1 November 2018, 1 February 2019, 2 May 2019, 2 August 2019, 1 November 2019, 31 January 2020, 29 April 2020, 31 July 2020, 30 October 2020, 29 January 2021, 30 April 2021, 30 July 2021 and 29 October 2021 in relation to the periodic update on the Suspension, as well as the announcements of the Company dated 30 July 2018 and 8 January 2020 in relation to the amendment of the Listing Rules which has come into effect on 1 August 2018 (collectively, referred to as the “**Previous Announcements**”). Unless defined otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Previous Announcements.

### **RECENT DEVELOPMENT OF RESUMPTION**

As mentioned in the Previous Announcements, the IBC has been established for the purpose of, among other things, conducting an independent investigation into the issues relating to the Acquisitions. Grant Thornton Advisory Services Limited (“**Independent Investigator**”) has been appointed as the independent investigator to the IBC to assist in the investigation. The Independent Investigator is in the process of preparing its independent investigation report.

The Company has also engaged BT Corporate Governance Limited (“**BTCGL**”) in September 2020 to conduct an independent internal control review in respect of the adequacy and

effectiveness of the Group's internal control systems in relation to the following areas, namely, investments in companies, conflict of interest, management of the Company, corporate governance, business transactions and risk assessment. BTCGL is in the process of conducting its review and preparing its report on the Group's internal control systems.

Up to the date of this announcement, the IBC's investigation into the affairs of the Acquisitions is still under progress. The Company is also seeking legal advice to address and resolve the SFC's concerns with the aim of resuming trading of the Shares. The Company has made further submission to the SFC in relation to its application for resumption of trading of the Shares in November 2021. However, the Company is not in a position to disclose the details due to its statutory secrecy obligations under the Securities and Futures Ordinance (Chapter 571, the Laws of Hong Kong). In view of the circumstances, the Company is not in a position to formulate any practicable resumption plan with a clear timeframe at this stage. The Company will continue to seek legal advice with a view to resuming trading of the Shares as soon as practicable.

## **BUSINESS UPDATE**

The Directors wish to point out that notwithstanding the Suspension, the Group has been carrying on its businesses as usual and continues to focus on the distribution and trading of pharmaceutical products and the provision of marketing and promotion services in the PRC.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Shares has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the SFC in accordance with Rule 8(1) Direction. As disclosed in the announcement of the Company dated 8 January 2020, the Stock Exchange has withheld exercising its right to delist the Company although trading in the Shares remained suspended on 31 January 2020. As such, trading in the Shares will continue to be suspended until further notice. The Company will endeavour to resume trading in the Shares as soon as practicable.

The Company reminds the Shareholders and potential investors that they should refer to the announcements published on the respective websites of the Stock Exchange and the Company for any information relating to the Group.

**The Company will keep the Shareholders and potential investors informed of any material development in connection with the above matters by way of periodic announcements and/or further announcement(s) as and when appropriate. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Wang Qiuqin**  
*Chairman & Executive Director*

Hong Kong, 31 January 2022

*As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*